•The early embryonic transcription factor DUX4 is active in many human cancers
•DUX4-expressing cancers are characterized by low anti-tumor immune activity
•DUX4 blocks interferon-γ-mediated induction of MHC class I and antigen presentation
•DUX4 is significantly associated with failure to respond to anti-CTLA-4 therapy
A team at Fred Hutchinson Cancer Research Center has identified a gene that could make immunotherapy treatments, specifically checkpoint inhibitors, work for a wider variety of cancer patients. The study, published today in Developmental Cell, found that when the DUX4 gene is expressed in cancer cells, it can prevent the cancer from being recognized and destroyed by the immune system.
The team, led by Drs...
Read More
Recent Comments